Ampicillin/Sulbactam

@article{Rafailidis2012AmpicillinSulbactam,
  title={Ampicillin/Sulbactam},
  author={Petros I. Rafailidis and Eleni N Ioannidou and Matthew E. Falagas},
  journal={Drugs},
  year={2012},
  volume={67},
  pages={1829-1849}
}
Ampicillin/sulbactam is a β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity against Gram-positive, Gram-negative and anaerobic bacteria. Data from comparative studies justify the use of ampicillin/sulbactam in a 2: 1 ratio in various severe bacterial infections. In comparative clinical trials, ampicillin/sulbactam has proved to be a significant drug in the therapeutic armamentarium for lower respiratory tract infections and aspiration pneumonia… 
Prevalence of Multidrug Resistant Acinetobacter baumannii in Hospitalized Patients in Lahore , Pakistan
TLDR
A. baumannii has achieved resistance against cephalosporin third and fourth generations, monobactam antibiotic, aminoglycoside, carbapenem, β-lactam antibiotics and tetracycline, confirmed by API testing system.
Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use
TLDR
The present review provides the status and knowledge concerning current β-lactamase inhibitors and an update on research efforts to identify and develop new and more efficient β- lactamases.
Review article MULTI DRUG RESISTANCE ACINETOBACTER BAUMANNII: A SYSTEMATIC REVIEW FOR MICROBIAL AND CLINICAL STUDY
TLDR
An overview of current knowledge on epidemiology, infections, mechanism of resistance and effective treatment options are briefly highlighted in this review of A. baumannii nosocomial infection and its consequences.
Ampicillin/sulbactam in elderly patients with community-acquired pneumonia
TLDR
In elderly patients without renal impairment and/or in severe infection with less susceptible pathogens, more frequent dosing of ampicillin 2 g/sulbactam 1 g can be necessary to avoid the risk of underdosing in CAP.
Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii
TLDR
Patients treated with cefoperazone/sulbactam therapy had a better clinical outcome and the mortality of patients receiving cef operazone-based combination therapy with imipenem/cilastatin seems to be the lowest.
Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance
TLDR
In this review, antibiotic resistance is discussed and new options for antibiotic discovery are discussed, focusing in particular on new alternatives aiming to disarm the bacteria or empower the host to avoid disease onset.
Antibiotic resistance breakers: current approaches and future directions
TLDR
It is posit that the broader field of ARB research can yet yield a greater diversity of more effective therapeutic agents than have been previously achieved, and offers a perspective on the future direction of the field.
Other β-lactam antibiotics
...
1
2
3
4
...

References

SHOWING 1-10 OF 122 REFERENCES
Experience with Ampicillin/Sulbactam in Severe Infections
  • G. Kanra
  • Medicine, Biology
    The Journal of international medical research
  • 2002
TLDR
The clinical efficacy profile of ampicillin/sulbactam and sultamicillin, combined with their excellent tolerability profile, make these agents attractive options for the management of many life-threatening infections in pediatric patients.
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem.
  • A. Levin
  • Biology, Medicine
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • 2002
TLDR
Co-administration of sulbactam with ampicillin or cefoperazone offers the potential of effective empirical therapy against Acinetobacter and other bacteria such as Enterobacteriaceae in institutions in which they are susceptible.
A Comparison of Parenteral Sulbactam/Ampicillin versus Clindamycin/Gentamicin in the Treatment of Pelvic Inflammatory Disease
TLDR
The bacteriological, clinical and overall responses for the sulbactam/ampicillin group were 100%, 85.7% and 85.4%, respectively, compared with 97.1%, 94.4% and 94.8%, for the clindamycin/gentamicin group.
Sulbactam/Ampicillin
TLDR
Sulbactam/ampicillin improves the therapeutic and prophylactic efficacy of an antibacterial of familiar safety, and must be seen as a worthwhile advance.
Susceptibility of Haemophilus influenzae type b to ampicillin-sulbactam
TLDR
Caution should be exercised in the use of this combination of Haemophilus influenzae type b and beta-lactamase-positive strains in treatment of meningitis, in which a high bacterial density is commonly encountered.
Efficacy of a β-Lactamase Inhibitor Combination for Serious Intra-abdominal Infections
TLDR
A double-blind trial was conducted in 385 patients with suspected bacterial intra-abdominal infections to compare the efficacy and safety of ampicillin-sulbactam with cefoxitin, and demonstrated no difference in safety or efficacy.
Which antibiotic is better for the treatment of infections of the lower respiratory tract?
...
1
2
3
4
5
...